Therapeutic Asset Ratings

6,371 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER Hematopoietic And Lymphoid System Neoplasm	Cancer Research UK	P2/3	BB (66)
Immunoglobulin G1 [de-449-lysine], anti-(human tau protein) (human-Mus musculus monoclonal E2814 ?1-chain), disulfide with human-Mus musculus monoclonal E2814 .kappa.-chain, dimer Alzheimer Disease	Eisai Inc.	P2/3	BB (66)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Diffuse Large B-Cell Lymphoma Activated B-Cell Type	Mayo Clinic	P2/3	BB (66)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type	Mayo Clinic	P2/3	BB (66)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Intravascular Large B-Cell Lymphoma	Mayo Clinic	P2/3	BB (66)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Mature B-Cell Lymphoma	BeOne Medicines	P2/3	BB (66)
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER Acute Myeloid Leukemia	University Hospital Tuebingen	P2/3	BB (66)
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER Myelodysplastic Syndrome	University Hospital Tuebingen	P2/3	BB (66)
Nivolumab Non-Hodgkin Lymphoma	University of Pittsburgh	P2/3	BB (66)
Nivolumab Myelodysplastic Syndrome	SCRI Development Innovations, LLC	P2/3	BB (66)
Donanemab APP-Related Brain And Vascular Amyloidosis	Michael Rafii, MD, PhD	P4	BB (65)
Donanemab Down Syndrome	Michael Rafii, MD, PhD	P4	BB (65)
Elranatamab Waldenstrom Macroglobulinemia	Anne Louise Tølbøll Sørensen	P4	BB (65)
Faricimab Wet Macular Degeneration	Faculty Hospital Kralovske Vinohrady	P4	BB (65)
Fremanezumab Acute Mountain Sickness	Insel Gruppe AG, University Hospital Bern	P4	BB (65)
Fremanezumab Menstrual Migraine	Insel Gruppe AG, University Hospital Bern	P4	BB (65)
Fremanezumab Migraine Without Aura	Hospital Clínico Universitario de Valladolid	P4	BB (65)
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER Multiple Sclerosis	Queen Mary University of London	P4	BB (65)
IMMUNOGLOBULIN G, ANTI-(HUMAN CALCITONIN GENE-RELATED PEPTIDE RECEPTOR) (HUMAN MONOCLONAL HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL LIGHT CHAIN, DIMER Headache Disorder	Beijing Tiantan Hospital	P4	BB (65)
Ipilimumab Kidney Cancer	Guliz Ozgun	P4	BB (65)
Ipilimumab Lung Cancer	University of Chicago	P4	BB (65)
Nirsevimab Viral Respiratory Tract Infection	Menzies School of Health Research	P4	BB (65)
Nirsevimab Respiratory Syncytial Virus Infectious Disease	Menzies School of Health Research	P4	BB (65)
Obinutuzumab Follicular Lymphoma	Institute of Hematology & Blood Diseases Hospital, China	P4	BB (65)
Pembrolizumab Immunotherapy	Ismail Gögenur	P4	BB (65)

Showing 326 to 350 of 6,371 assets

PreviousPage 14 of 255Next